How did SUPN's Q4 earnings surprise impact its annual performance?

Supernus Pharmaceuticals (SUPN) experienced a decline in its Q4 net income, with a reported $15.33 million, compared to the previous year's $18.79 million, and an EPS surprise of -0.25, indicating a negative earnings surprise. This negative trend was part of a broader downturn in performance over the past year, with total revenue falling to $174.16 million in 2024, down from $227.6 million in 2023.

The decline in Q4 earnings had a significant impact on the company's annual performance, with the net income and revenue figures representing a low point for Supernus Pharmaceuticals in 2024. The EPS surprise of -0.25 reflects the market's disappointment with the company's performance, which could lead to downward pressure on the stock price.

|code|Ticker|Name|Date|Net Income|market_code|
|---|---|---|---|---|---|
|SUPN|SUPN.O|Supernus|2024 Q1|124000|185|
|SUPN|SUPN.O|Supernus|2024 Q2|1.9916E7|185|
|SUPN|SUPN.O|Supernus|2024 Q3|3.8497E7|185|
|SUPN|SUPN.O|Supernus|2024 Q4|1.5328E7|185|

|code|Ticker|Name|Date|Diluted EPS|market_code|
|---|---|---|---|---|---|
|SUPN|SUPN.O|Supernus|2024 Q1|0|185|
|SUPN|SUPN.O|Supernus|2024 Q2|0.36|185|
|SUPN|SUPN.O|Supernus|2024 Q3|0.69|185|

|code|Ticker|Name|Date|Revenue Surprise|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|SUPN|SUPN.O|Supernus|2024 Q1|-2186000|1.43644E8|185|
|SUPN|SUPN.O|Supernus|2024 Q2|1.9475E7|1.68325E8|185|
|SUPN|SUPN.O|Supernus|2024 Q3|1.839E7|1.75689E8|185|
|SUPN|SUPN.O|Supernus|2024 Q4|1.8909E7|1.74159E8|185|